AccreditationΒΆ
Please note the following disclaimers around accreditation. Some may not be presented in the cancer DSS.
Pipeline Accreditation
Until the end-to-end whole genome sequencing (WGS) pipeline is accredited to ISO 15189;2012 standards, it is essential that all findings from WGS reported by the NHS GLHs are validated by an orthogonal test in a UKAS accredited laboratory. Please see the NHS England Guidelines for Cancer Whole Genome Sequencing & Next Generation Sequencing Panel Interpretation & Reporting guidance document for further details.
Tumour Only Accreditation
Tumour-only analysis (i.e. performed without an accompanying matched germline sample) is not yet in the scope of accreditation for the Genomics England Pipeline. Therefore, any finding should be validated before use.
Dragen v4 Accreditation
PLEASE NOTE: some findings in this section are not UKAS accredited to ISO 15189. Dragen software for calling somatic copy number variants (CNVs) and Pelops algorithm for identifying DUX4 rearrangements are not currently included in the schedule of accreditation issued by UKAS. Please refer to the schedule of accreditation <a href=https://www.ukas.com/wp-content/uploads/schedule_uploads/00007/10170-Medical-Single.pdf
Global Analysis Plots Accreditation
PLEASE NOTE: some findings in this section are not UKAS accredited to ISO 15189. Mutational signatures are not currently included in the schedule of accreditation issued by UKAS. Please refer to the [schedule of accreditation] (https://www.ukas.com/wp-content/uploads/schedule_uploads/00007/10170-Medical-Single.pdf) for more information.